TrialThe oncologist2025

NCI 10211: a phase II, single-arm study of berzosertib in combination with irinotecan in patients with advanced TP53 mutant gastroesophageal cancer.

Margaret C Wheless et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.